heparegenix-logo.png
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
10 juil. 2024 03h00 HE | HepaRegeniX GmbH
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...
heparegenix-logo.png
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
14 mars 2024 11h35 HE | HepaRegeniX GmbH
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniXHRX-215 proved to be safe and...